Myungin Pharm (KRX: 317450)
Who is buying Myungin Pharm?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩0.9bn ($1M) of Myungin Pharm, the 237th largest foreign net sale among 832 KOSPI stocks. Institutions net sold ₩1.0bn ($1M) and retail investors net bought ₩2.1bn ($2M) over the same window. Foreigners were net buyers on 5 of the 20 sessions.
Foreign investors hold 0.79% of Myungin Pharm's listed shares (KRX ownership data as of Oct 13, 2026), down from 0.87% twenty sessions earlier and 1.24% a year ago.
The stock closed at ₩40,900 on Oct 13, 2026: -6.94% over 20 sessions, -40.64% year-to-date, -58.27% over one year. The 52-week range is ₩39,100 – ₩118,700.
At ₩40,900 the stock trades at 6.09× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩40,900 | ₩-0.2bn | ₩0.0bn | +₩0.2bn |
| 2026-10-12 | ₩41,000 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-10-08 | ₩42,550 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-10-07 | ₩43,350 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-10-06 | ₩43,350 | ₩-0.3bn | ₩0.0bn | +₩0.3bn |
| 2026-10-02 | ₩43,650 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-10-01 | ₩44,800 | +₩0.7bn | ₩-0.2bn | ₩-0.5bn |
| 2026-09-30 | ₩42,250 | +₩0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-09-29 | ₩42,150 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-09-28 | ₩42,400 | +₩0.0bn | ₩0.0bn | ₩-0.0bn |
| 2026-09-23 | ₩42,000 | ₩-0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-22 | ₩42,050 | ₩-0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-09-21 | ₩42,250 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-18 | ₩42,550 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-17 | ₩42,300 | +₩0.6bn | ₩-0.2bn | ₩-0.3bn |
| 2026-09-16 | ₩42,550 | ₩-0.3bn | ₩-0.1bn | +₩0.4bn |
| 2026-09-15 | ₩43,400 | ₩-0.0bn | ₩-0.2bn | +₩0.2bn |
| 2026-09-14 | ₩43,400 | +₩0.0bn | ₩-0.2bn | +₩0.1bn |
| 2026-09-11 | ₩44,100 | ₩-0.1bn | +₩0.1bn | +₩0.0bn |
| 2026-09-10 | ₩43,850 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-09 | ₩43,950 | +₩0.1bn | ₩-0.3bn | +₩0.2bn |
| 2026-09-08 | ₩43,950 | ₩-0.2bn | +₩0.0bn | +₩0.3bn |
| 2026-09-07 | ₩44,550 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-04 | ₩44,650 | ₩-0.1bn | ₩-0.1bn | +₩0.2bn |
| 2026-09-03 | ₩44,650 | ₩-0.4bn | ₩-0.0bn | +₩0.4bn |
| 2026-09-02 | ₩45,500 | ₩-0.2bn | +₩0.1bn | +₩0.1bn |
| 2026-09-01 | ₩45,800 | +₩0.1bn | +₩0.1bn | ₩-0.2bn |
| 2026-08-31 | ₩46,100 | ₩-0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-08-28 | ₩46,400 | +₩0.3bn | ₩-0.1bn | ₩-0.1bn |
| 2026-08-27 | ₩45,700 | ₩-0.2bn | ₩-0.1bn | +₩0.3bn |
| 2026-08-26 | ₩46,350 | +₩0.1bn | ₩-0.1bn | +₩0.0bn |
| 2026-08-25 | ₩45,200 | ₩-0.1bn | ₩-0.1bn | +₩0.2bn |
| 2026-08-24 | ₩45,900 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-08-21 | ₩45,400 | ₩-0.4bn | +₩0.1bn | +₩0.3bn |
| 2026-08-20 | ₩47,150 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-19 | ₩45,800 | ₩-0.6bn | +₩0.1bn | +₩0.3bn |
| 2026-08-18 | ₩45,400 | ₩-0.7bn | ₩-0.1bn | +₩0.8bn |
| 2026-08-14 | ₩47,650 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-08-13 | ₩47,200 | ₩-0.6bn | +₩0.2bn | +₩0.4bn |
| 2026-08-12 | ₩48,350 | ₩-0.6bn | +₩0.4bn | +₩0.2bn |
| 2026-08-11 | ₩49,550 | ₩-0.2bn | +₩0.4bn | ₩-0.3bn |
| 2026-08-10 | ₩48,300 | ₩-0.3bn | +₩0.7bn | ₩-0.4bn |
| 2026-08-07 | ₩46,050 | +₩0.1bn | +₩0.2bn | ₩-0.3bn |
| 2026-08-06 | ₩45,150 | +₩0.4bn | ₩-0.1bn | ₩-0.3bn |
| 2026-08-05 | ₩43,400 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-08-04 | ₩43,350 | +₩0.1bn | ₩-0.0bn | ₩-0.0bn |
| 2026-08-03 | ₩42,200 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-07-31 | ₩42,000 | +₩0.2bn | +₩0.0bn | ₩-0.3bn |
| 2026-07-30 | ₩41,250 | +₩0.6bn | +₩0.0bn | ₩-0.6bn |
| 2026-07-29 | ₩40,100 | +₩0.4bn | ₩-0.0bn | ₩-0.3bn |
| 2026-07-28 | ₩40,800 | ₩-0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-27 | ₩42,800 | ₩-0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-24 | ₩41,650 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-07-23 | ₩42,450 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-07-22 | ₩40,600 | +₩0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-21 | ₩41,000 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-20 | ₩41,000 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-16 | ₩42,550 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-15 | ₩42,600 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-14 | ₩42,000 | +₩0.0bn | ₩-0.1bn | +₩0.0bn |
| 2026-07-13 | ₩42,400 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.2bn | $-0M | ₩0.0bn | +₩0.2bn |
| 5 days | ₩-1.0bn | $-1M | ₩-0.0bn | +₩1.0bn |
| 20 days | ₩-0.9bn | $-1M | ₩-1.0bn | +₩2.1bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Myungin Pharm stock?
Over the last 5 sessions foreign investors net sold ₩1.0bn ($1M) of Myungin Pharm; over 60 sessions they net sold ₩3.7bn ($3M); since Jan 1, 2026 they net sold ₩2.8bn ($2M). Over 20 sessions the stock is the 237th largest foreign net sale among 832 KOSPI stocks.
How much of Myungin Pharm do foreign investors own?
Foreign investors own 0.79% of Myungin Pharm's shares as of Oct 13, 2026, versus 1.24% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩1.0bn ($1M) and retail investors net bought ₩2.1bn ($2M) of Myungin Pharm. Retail investors have been absorbing what foreigners and institutions are selling.
Is Myungin Pharm listed on KOSPI or KOSDAQ?
Myungin Pharm (명인제약) trades on KOSPI under KRX code 317450 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.4B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2025 | ₩287bn ($215M) | – | ₩92bn ($69M) | ₩81bn ($61M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.